Vitamin D status in young HIV infected women of various ethnic origins: Incidence of vitamin D deficiency and possible impact on bone density

Clinical Nutrition

Volumn 32, Issue 1, 2013, Pages 83-87

  Shahar, Eduardo ^a,b,d   Segal, Elena ^a,d   Rozen, Geila S ^e   Shen Orr, Zila ^c   Hassoun, Gamal ^b   Kedem, Eynat ^b   Pollack, Shimon ^b,d   Ish Shalom, Sophia ^a,d  

^a Bone and Mineral Metabolism Unit   (Israel)

^b Institute of Allergy Clinical Immunology and AIDS   (Israel)

^c Endocrine Laboratory   (Israel)

^d TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^e The Clinical Nutrition Department   (Israel)

Author keywords

Bone density; Ethnic origin; HIV infection; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ANTIRETROVIRUS AGENT; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; PROCOLLAGEN TYPE 1 NITROGENOUS PROPEPTIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VIRUS RNA; VITAMIN D;

ADULT; ARTICLE; BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; CALCIUM INTAKE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CLOTHING; CONTROLLED STUDY; DISEASE DURATION; ETHIOPIAN; ETHNIC DIFFERENCE; FEMALE; FEMUR NECK; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISRAEL; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORBIDITY; PATIENT MONITORING; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; RACE; RACE DIFFERENCE; REAL TIME POLYMERASE CHAIN REACTION; SUN EXPOSURE; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

25-HYDROXYVITAMIN D 2; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIFEDIOL; CALCIUM, DIETARY; CLOTHING; DIET; ETHIOPIA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INCIDENCE; ISRAEL; MIDDLE AGED; NUTRITIONAL STATUS; OSTEOPOROSIS; SUNLIGHT; VITAMIN D DEFICIENCY;

EID: 84872616820     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.05.022     Document Type: Article

References (41)

1. Brown T.T., Qaqish R.B. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006, 20:2165-2174.
2. Teichmann J., Lange U., Discher T., Lohmeyer J., Stracke H., Bretzel P.G. Growth hormone and bone mineral density in HIV-1 infected male subjects. Eur J Med Res 2008, 13:173-178.
3. Fessel W.J., Hurley L.B. Is HIV sequestered in bone? Possible implications of virological and immunological findings in some HIV-infected patients with bone disease. AIDS 2003, 17:255-257.
4. Cozzolino M., Vidal M., Arcidiacono M.V., Tebas P., Yarashesky K.E., Dusso A.S. HIV-protease inhibitors impair vitamin D bioactivation to 1,25 dihydroxyvitamin D. AIDS 2003, 17:513-520.
5. Amiel C., Ostertag A., Slama L., Baudoin C., N'Guyen T., Lajeunie E., et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004, 19:402-409.
6. Fausto A., Bongiovanni M., Cicconi P., Menicagli L., Ligabo E.V., Melzi S., et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone 2006, 38:893-897.
7. Kühne C.A., Heufelder A.M., Hofbauer L.C. Bone and mineral metabolism in human immunodeficiency virus infection. J Bone Miner Res 2001, 16:2-9.
8. Cazanave C., Dupon M., Lavignolle-Aurillac V., Barthe N., Lawson-Ayayi S., Mehsen N., et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008, 22:395-402.
9. Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14. F63-FF7.
10. Moore A.L., Vashisht A., Sabin C.A., Mocroft A., Madge S., Phillips A.N., et al. Reduced bone mineral density in HIV-positive individuals. AIDS 2001, 15:1731-1733.
11. Fernandez-Rivera J., Garcia R., Lozano F., Macias J., Garcia-Garcia J.A., Mira J.A., et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003, 4:337-346.
12. Madeddu G., Spanu A., Solinas P., Calia G.M., Lovigu C., Chessa F., et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004, 48:39-48.
13. Landonio S., Quirino T., Bonfanti P., Gabris A., Boccassini L., Gulisano C., et al. Osteopenia and osteoporosis in HIV+ patients, untreated or receiving HAART. Biomed Pharmacother 2004, 58:505-508.
14. Nolan D., Upton R., McKinnon E., John M., James I., Adler B., et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS 2001, 15:1275-1280.
15. Rivas P., Gorgolas M., Garcia-Delgado R., Diaz-Curiel M., Goyenechea A., Fernandez-Guerrero M.L. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med 2008, 9:89-95.
16. Duvivier C., Kolta S., Assoumou L., Ghosn J., Rozenberg S., Murphy R., et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009, 27:817-824.
17. Brown T.T., Ruppe M.D., Kassner R., Kumar P., Kehoe T., Dobs A.S., et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004, 89:1200-1206.
18. Bouvier G. Protease inhibitors can interfere with vitamin D metabolism. HIV Clinician 2009, 21:9-10.
19. Brown T.T., McComsey G., King M., Qaqish R., Bernstein B., Da Silva B. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009, 51:554-561.
20. Gallant J.E., Staszewski S., Pozniak A.L., DeJesus E., Suleiman J.M., Miller M.D., et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191-201.
21. Villamor E. A potential role for vitamin D on HIV infection?. Nutr Rev 2006, 64:226-233.
22. Dao C.N., Patel P., Overton E.T., Rhame F., Pals S.L., Johnson C., et al. Low vitamin D among HIV infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011, 52:396-405.
23. Curtis J.R., Smith B., Weaver M., Landers K., Lopez-Ben R., Raper J.L., et al. Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy. AIDS Res Hum Retroviruses 2006, 22:125-131.
24. Kim J.H., Gandhi V., Psevdos G., Espinoza F., Park J., Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New-York City. AIDS Res Hum Retroviruses 2012, 28:235-239.
25. Gibellini D., De Crings E., Ponti C., Cimatti L., Borderi M., Tschon M., et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008, 80:1507-1514.
26. Loiseau-Pérès S., Delaunay C., Poupon S., Lespessailles E., Ballouche N., Arsac P., et al. Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Jt Bone Spine 2002, 69:482-485.
27. Wang L., Mondal D., La Russa V.F., Agrawal K.C. Suppression of clonogenic potential of human bone marrow mesenchymal stem cells by HIV type 1: putative role of HIV type tat protein and inflammatory cytokines. AIDS Res Hum Retroviruses 2002, 18:917-931.
28. Breen E.C. Pro-and Anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacol Ther 2002, 95:295-304.
29. Ueland T., Froland S.S., Bollerslev J., Aukrust P. Increased levels of biochemical markers of bone turnover in relation to persistent activation in common variable immunodeficiency. Eur J Clin Invest 2001, 31:72-78.
30. Clowes J.A., Riggs B.L., Khosla S. The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005, 208:207-227.
31. Seminari E., Castagna A., Soldarini A., Galli L., Fusetti G., Dorigatti F., et al. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005, 6:145-150.
32. Mora S., Zamproni I., Cafarelli L., Giacomet V., Erba P., Zuccotti G., et al. Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. AIDS 2007, 31:1129-1135.
33. Konishi M., Takahasi K., Yoshimoto E., Uno K., Kasahara K., Mikasa K. Association between osteopenia/osteoporosis and the serum RANKL in HIV- infected patients. AIDS 2005, 19:1240-1241.
34. Camozzi V., Tossi A., Simoni E., Pagani F., Francucci C.M., Moro L. Role of biochemical markers of bone remodeling in clinical practice. J Endocrinol Invest 2007, 30(6 Suppl.):13-17.
35. Grund B., Peng G., Gibert C.L., Hoy J.F., Isaksson R.L., Shlay J.C., et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009, 23:1519-1529. INSIGHT SMART Body Composition Substudy Group.
36. Harris S.S. Vitamin D and African Americans. J Nutr 2006, 136:1126-1129.
37. Mueller N.J., Fux C.A., Ledergerber B., Elzi L., Schmid P., Dang T., et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010, 24:1127-1134. Swiss HIV Cohort Study.
38. Conde D.M., Silva I.T., Amaral W.N., Finotti M.F., Ferreuira R.G., Costa-Paiva L., et al. HIV, reproductive aging, and health implications in women: a literature review. Menopause 2009, 16:199-213.
39. Clay P.G., Voss L.E., Williams C., Daume E.C. Valid treatment options for osteoporosis and osteopenia in HIV-infected persons. Ann Pharmacother 2008, 42:670-679.
40. Young B., Dao C.N., Buchacz K., Baker R., Brooks J.T. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011, 52:1061-1068.
41. Yin M.T., McMahon D.J., Ferris D.C., Zhang C.A., Shu A., Staron R., et al. Low bone mass and high bone turnover in postmenopausal human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2010, 95:620-629.